DiaMedica Therapeutics Inc (DMAC) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $8.23
• Market Cap: $442.66M
• EPS: $-0.71
• 52-Week High: $10.42
• 52-Week Low: $3.19

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, specialized in developing innovative therapies for neurological and kidney diseases. The company's lead candidate, DM199, targets the enhancement of renal function in patients suffering from diabetic kidney disease, showcasing its commitment to addressing critical unmet medical needs. With a robust pipeline and a strong emphasis on clinical innovation, DiaMedica is strategically position...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for DiaMedica Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does DMAC pay dividends?

DiaMedica Therapeutics Inc (DMAC) does not currently pay a regular dividend.

What is DMAC's market cap?

DiaMedica Therapeutics Inc (DMAC) has a market capitalization of $442.66M with a current stock price of $8.23.